GERN Stock Price | Geron Corporation P/E, Revenue, EPS, & Forecasts

Geron Corporation • GERN

GERN current price

$3.92+71.56%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

-2.24%

+0.77%

-11.67%

-17.34%

+71.56%

MAX

+22.54%

About Geron Corporation

Ticker

GERN

Trading on

NASDAQ

ISIN

US3741631036

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. John A. Scarlett M.D.

Headquarters

919 East Hillsdale Boulevard, Foster City, CA, United States, 94404

Employees

141

Website

geron.com

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Metrics

BasicAdvanced

Market cap

$2.41B

P/E ratio

EPS

-$0.32

Dividend Yield

0.00%

Beta

0.52

Forward P/E ratio

EBIDTA

$-207M

Ex dividend date

Price & volume

Market cap

$2.41B

Average daily volume

7.1M

90-day return

-11.67%

30-day return

0.77%

7-day return

-2.24%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

-2.38

Trailing P/E

Price to sales

81.61

Price to book

8.23

Earnings

EPS

-$0.32

EPS estimate (current quarter)

-$0.08

EPS estimate (next quarter)

-$0.06

EBITDA

$-207M

Revenues (TTM)

$29.5M

Revenues per share (TTM)

$0.05

Technicals

Beta

0.52

52-week High

$5.34

52-week Low

$1.64

50-day moving average

$4.09

200-day moving average

$4.01

Short ratio

7.03

Short %

11.04%

Management effectiveness

ROE (TTM)

69.03%

ROA (TTM)

30.30%

Profit margin

0.00%

Gross profit margin

$-93.7M

Operating margin

99.80%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

17,138.40%

Share stats

Outstanding Shares

605M

Float

558M

Insiders %

0.09%

Institutions %

85.40%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 10 analysts.

Average price target

$7.61

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.09

-$0.10

10.00%

Q4 • 23Beat

-$0.09

-$0.10

10.00%

Q1 • 24Beat

-$0.10

Q2 • 24Beat

-$0.04

-$0.08

50.00%

Q3 • 24Beat

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0.9M

$-67.4M

7,639.80%

Q2 • 24

$28.3M

$-26.4M

93.55%

Q3 • 24

3,105.33%

60.75%

98.78%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$449M

$143M

31.75%

Q2 • 24

$403M

$110M

27.42%

Q3 • 24

10.39%

22.62%

13.65%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-53.5M

$-36.1M

$16.8M

$-53.7M

Q2 • 24

$-58.9M

$-0.6M

$3.6M

$-58.9M

Q3 • 24

10.22%

98.47%

78.74%

9.79%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Neutral

+1.5

0.25

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Geron Corporation share?

Geron Corporation shares are currently traded for $3.92 per share.

How many shares does Geron Corporation have?

Geron Corporation currently has 605M shares.

Does Geron Corporation pay dividends?

No, Geron Corporation doesn't pay dividends.

What is Geron Corporation 52 week high?

Geron Corporation 52 week high is $5.34.

What is Geron Corporation 52 week low?

Geron Corporation 52 week low is $1.64.

What is the 200-day moving average of Geron Corporation?

Geron Corporation 200-day moving average is $4.01.

Who is Geron Corporation CEO?

The CEO of Geron Corporation is Dr. John A. Scarlett M.D..

How many employees Geron Corporation has?

Geron Corporation has 141 employees.

What is the market cap of Geron Corporation?

The market cap of Geron Corporation is $2.41B.

What is the P/E of Geron Corporation?

The current P/E of Geron Corporation is null.

What is the EPS of Geron Corporation?

The EPS of Geron Corporation is -$0.32.

What is the PEG Ratio of Geron Corporation?

The PEG Ration of Geron Corporation is -2.38.

What do analysts say about Geron Corporation?

According to the analysts Geron Corporation is considered a buy.

Geron Corporation news

thumbs_up_down

•Neutral

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myel.

Business Wire•16h ago

thumbs_up_down

•Neutral

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced new analyses presented at the 66th American Society of Hematology (ASH) Annual Meeting from the IMerge clinical trial in patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia suggesting clinical activity of first-in-class telomerase inhibitor RYTELO™ (imetelstat).

Business Wire•10 Dec 2024, 14:00

thumbs_up_down

•Neutral

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced results from an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety results from the dose escalation Part 1 suggest the tolerability of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, in.

Business Wire•10 Dec 2024, 14:00